Results 201 to 210 of about 255,512 (289)
Radiotherapy plus immune checkpoint inhibitors versus immune checkpoint inhibitors alone for non-small cell lung cancer with bone metastases: a systematic review and meta-analysis of comparative cohort studies. [PDF]
Ruan Y +6 more
europepmc +1 more source
Macrophage Extracellular Traps in Immunity and Cancer
As a macrophage‐mediated innate defense mechanism, the dysregulated release of METs drives chronic inflammation and influences tumor progression. Furthermore, METs exhibit a functional duality within the tumor microenvironment, capable of both promoting and suppressing tumor development.
Junyao Li +5 more
wiley +1 more source
Correction: Immune checkpoint inhibitors and cardiovascular toxicity: immunology, pathophysiology, diagnosis, and management. [PDF]
Becker RC.
europepmc +1 more source
Schematic illustration of the synthesis protocol for Fe‐SH@Fn, an AML‐targeted nanoplatform engineered to co‐deliver shikonin (SH) and Fe3+, synergistically boosting antitumor immunity via ferroptosis induction and immunogenic cell death (ICD). ABSTRACT Acute myeloid leukemia (AML) remains a therapeutic challenge due to its low immunogenicity and ...
Shangqin Yang +9 more
wiley +1 more source
Guillain-Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study. [PDF]
Cabon J +6 more
europepmc +1 more source
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu +7 more
wiley +1 more source
Meta-analysis of tuberculosis incidence and risk in cancer patients treated with immune checkpoint inhibitors. [PDF]
Ming H, Fu B, Chen X, Hu W, Yu H.
europepmc +1 more source
We developed an implantable dual‐drug depot using GelMA for bone metastasis treatment, co‐delivering MSA‐2 and αB7‐H3‐loaded CaCO3 microparticles. Sustained release from GelMA scaffold enables MSA‐2 to activate STING signaling and enhance T‐cell infiltration and activation, while sequentially released αB7‐H3 blocks MSA‐2‐induced B7‐H3 upregulation ...
Qijun Lin +10 more
wiley +1 more source

